Short-Term Outcomes of 3 Monthly intravitreal Faricimab On Different Subtypes of Neovascular Age-Related Macular Degeneration.

Asako TanakaMasayuki HataMemiri TsuchikawaNaoko Ueda-Arakawa Ueda-ArakawaHiroshi TamuraManabu MiyataAyako TakahashiAi KidoYuki MuraokaMasahiro MiyakeSotaro OotoAkitaka Tsujikawa

Published in: Clinical ophthalmology (Auckland, N.Z.) (2024)

Faricimab demonstrated significant effectiveness and safety in treatment-naïve nvAMD patients, particularly for PCV and PNV eyes. ELM presence and IRF is predictive of visual outcomes.

Keyphrases

age related macular degeneration
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
vascular endothelial growth factor
prognostic factors
optical coherence tomography
dendritic cells
immune response
patient reported outcomes
combination therapy
adipose tissue